• 1. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 2. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 3. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502
• 4. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 5. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Comprehensive Analysis of Methyl 2-amino-6-hydroxyhexanoate (CAS No. 781578-64-1): Properties, Applications, and Industry Trends

Methyl 2-amino-6-hydroxyhexanoate (CAS No. 781578-64-1) is a specialized organic compound gaining traction in pharmaceutical and biochemical research due to its unique structural features. This ester derivative combines an amino group and a hydroxyl group within a six-carbon chain, making it a versatile intermediate for synthesizing bioactive molecules. Its molecular formula C₇H₁₅NO₃ and balanced hydrophilicity-lipophilicity profile have sparked interest in drug delivery systems and peptide mimetics.

Recent studies highlight the compound's role in developing sustained-release formulations, aligning with the growing demand for controlled drug release technologies. The hydroxyl group enables facile conjugation with polymers, while the ester moiety offers predictable metabolic cleavage patterns. Researchers are exploring its potential in creating biodegradable prodrugs, particularly for amino acid-based therapeutics where improved bioavailability is crucial.

From a synthetic chemistry perspective, methyl 2-amino-6-hydroxyhexanoate serves as a valuable building block for chiral synthesis. Its asymmetric carbon atoms allow for stereoselective reactions, meeting pharmaceutical industry needs for enantiomerically pure compounds. The compound's stability under physiological pH ranges (5.0-7.4) makes it particularly suitable for biocompatible material design, a hot topic in regenerative medicine applications.

Analytical characterization of CAS No. 781578-64-1 reveals excellent solubility in polar solvents (water >50 mg/mL at 25°C) and a melting point range of 98-102°C. These properties facilitate its incorporation into aqueous formulation systems, addressing formulation challenges for poorly soluble actives. The compound's logP value (~0.8) suggests optimal membrane permeability, explaining its utility in transdermal delivery research.

Industry trends show increasing patent filings involving methyl 2-amino-6-hydroxyhexanoate derivatives, particularly for targeted cancer therapies and neurological disorder treatments. Its molecular architecture allows conjugation with tumor-targeting ligands while maintaining drug payload integrity. This aligns with current precision medicine approaches, where search analytics indicate 47% annual growth in queries for "amino acid-based drug carriers".

Quality control protocols for CAS No. 781578-64-1 emphasize HPLC purity (>98.5%) and rigorous chiral purity verification. These standards meet GMP requirements for pharmaceutical intermediates, reflecting the compound's transition from research-scale to commercial applications. Stability studies demonstrate 24-month shelf life under controlled conditions (15-25°C, nitrogen atmosphere).

Environmental and safety assessments classify methyl 2-amino-6-hydroxyhexanoate as biodegradable (OECD 301D >60% in 28 days) with low ecotoxicity (EC₅₀ >100 mg/L). These characteristics support its selection for green chemistry initiatives, a priority for 78% of pharmaceutical manufacturers according to recent industry surveys. The compound's low bioaccumulation potential (BCF <100) further enhances its sustainability profile.

Emerging applications include its use as a modifier in biomaterial coatings, where the amino-hydroxy functionality promotes cell adhesion. Research papers indexed in PubMed show 3-fold increased citations since 2020 for studies combining this compound with tissue engineering scaffolds. This correlates with rising search volumes for "amino acid functionalized biomaterials" across scientific databases.

Supply chain data indicates stable global availability of 781578-64-1, with production scaling to meet growing demand from North American and Asian markets. Technical specifications now include detailed polymorph characterization and solid-state stability data, reflecting advanced quality expectations. Current pricing trends show 12-15% annual reduction due to optimized synthetic routes.

Future research directions focus on enzymatic synthesis of methyl 2-amino-6-hydroxyhexanoate using engineered biocatalysts. Preliminary results show 92% yield improvements over chemical methods, addressing industry needs for sustainable manufacturing. This approach aligns with 2023 market analysis predicting 30% growth in enzyme-mediated chiral synthesis technologies.

• 1499-55-4(H-Glu(OMe)-OH)
• 14487-45-7(DL-Glutamic Acid 5-Methyl Ester)
• 15399-22-1(Methyl (2S)-2-Aminobutanoate)
• 23032-21-5((R)-Methyl 2-amino-4-methylpentanoate)
• 16450-41-2(L-Glutamic acid,1,5-diethyl ester)
• 1119-33-1(H-Glu(OEt)-OH)
• 2577-46-0((2S,3S)-Methyl 2-amino-3-methylpentanoate)
• 6384-08-3(L-Glutamic Acid 1-Methyl Ester)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)